Close Menu
Home › Celsius Therapeutics to Use Single-Cell Platform in Three New Immuno-Oncology Collaborations

Celsius Therapeutics to Use Single-Cell Platform in Three New Immuno-Oncology Collaborations

Sep 19, 2019
|
staff reporter

NEW YORK – Celsius Therapeutics said today that it has signed collaboration agreements with the Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy in France, and the University Health Network in Toronto, Canada, under which it will use its proprietary single-cell genomics platform to test tissue samples from cancer patients receiving immune checkpoint inhibitor treatment.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
13
Featured Webinar

Targeted Detection of MET and NTRK Oncogenic Variants in Routine Molecular Analysis

This webinar will discuss advances in detecting MET and NTRK variants in tumor samples, which can help clinicians determine the appropriate therapy for cancer patients.

Nov
14
Featured Webinar

High-Performance Variant Detection in Somatic Cancer Testing with an Integrated NGS Solution

Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

What's Popular?

In Cancer

  1. Colon Cancer Recurrence Clues Identified in Post-Treatment ctDNA Detection

  2. CHMP Issues Positive Decision for Keytruda in First Line PD-L1 Positive Head, Neck Cancer

    Premium

  3. Tumor-Derived Organoids ID Colorectal Cancer Patients Who Don't Respond to Irinotecan-Based Chemo

    Premium

  4. Gut Microbiome May Affect Cancer Patients' Responses to Immunotherapy, Emerging Research Shows

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.